Hindustan Bio Sciences Ltd

Hindustan Bio Sciences Ltd's latest Q3 FY26 results show a slight recovery with net sales of ₹0.38 crores and a net profit of ₹0.08 crores, but significant revenue volatility and a high debt-to-equity ratio raise concerns about the sustainability of its business model. Investors should monitor future performance closely for signs of stability.

The next results date for Hindustan Bio Sciences Ltd is 30 May 2026.

Hindustan Bio Sciences Ltd recorded a 5.18% gain over the week ending 10 April 2026, closing at Rs.8.94 from Rs.8.50. This performance was slightly below the Sensex’s 5.34% rise during the same period, reflecting a mixed but cautiously optimistic market response amid significant technical developments and a rating upgrade by MarketsMOJO.

Hindustan Bio Sciences Ltd delivered a strong weekly performance, surging 21.01% from Rs.6.76 to Rs.8.18 between 2 and 6 February 2026, significantly outperforming the Sensex’s modest 1.51% gain over the same period. This rally unfolded amid a backdrop of fundamental downgrades, valuation concerns, and mixed technical signals, reflecting a complex interplay of market optimism and caution.

The next results date for Hindustan Bio Sciences Ltd is January 31, 2026.

On 28-Nov, Hindustan Bio Sciences Ltd witnessed a notable decline in its share price, closing at ₹6.10, down by ₹0.20 or 3.17% as of 08:35 PM. This drop marks a fresh 52-week low for the stock, reflecting ongoing challenges despite increased investor activity.

As of 18-Nov, Hindustan Bio Sciences Ltd's stock price is Rs 6.59, down -4.91%, and has fallen -9.6% over the last two days. The stock is trading below all key moving averages and is close to its 52-week low, with significantly decreased investor participation.

As of November 3, 2025, Hind.Bio Science is considered overvalued with a PE ratio of 54.70, significantly higher than its peers, and has underperformed the Sensex year-to-date, indicating a risky investment.

Hind.Bio Science has experienced fluctuating financial performance, with net sales declining from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, though profitability metrics show signs of recovery, particularly with an operating profit margin improving to 12.35% in Mar'25. Total liabilities and assets have also decreased during this period, while cash flow from operations has remained stagnant.

As of 30-Oct, Hindustan Bio Sciences Ltd's stock price is at 7.14, up 5.0% recently, but it has declined 15.00% over the past month and 30.07% year-to-date. Despite a short-term gain, the stock's delivery volume has dropped significantly, indicating reduced investor interest.

As of 24-Oct, Hindustan Bio Sciences Ltd's stock price is Rs. 6.57, down 9.88% and at a new 52-week low, having declined 26.92% over the past three days. The stock has underperformed its sector and major benchmarks, despite a notable increase in delivery volume, indicating limited investor interest amidst a broader market recovery.

As of 23-Oct, Hindustan Bio Sciences Ltd's stock price is at 7.29, down 10.0%, and has underperformed significantly with an 18.91% total return drop over two days. It is trading below all moving averages, indicating a bearish trend, and has seen a 65.19% decrease in delivery volume, reflecting reduced investor participation.